Pre-treatment visualization of predicted radiation-induced acute alopecia in brain tumour patients.
Alopecia
Brain tumour
Hair loss
Neuro-oncology
Prediction
Radiotherapy
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
27
12
2021
revised:
08
02
2022
accepted:
10
02
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Temporary alopecia is a common side-effect in brain tumour patients receiving cranial radiotherapy with a significant psychological burden for the affected patient. The purpose of this study was to generate a method in our treatment planning system (TPS) to visualize the expected radiation-induced alopecia 4 weeks after treatment, in order to inform the patients thereupon before the start of radiotherapy. A pilot study was conducted in ten patients receiving hypo- (HF) or conventionally fractionated (CF) photon beam Volumetric Modulated Arc Therapy (VMAT) for an intracranial lesion. Dose calculations were correlated to visible alopecia four weeks after the end of treatment to create a structure predictive of alopecia in our TPS. These alopecia structures for both fractionation schedules were validated in two cohorts of 69 HF and 78 CF patients undergoing radiotherapy between 2016 and 2019. In the pilot cohort, a total physical dose of 4 Gy for HF and 12.6 Gy for CF radiotherapy were found to be predictive of alopecia 4 weeks after treatment. Applying these doses to our validation cohort, we found an accurate prediction of alopecia in 59/69 (86%) HF and 73/78 (96%) CF patients. For the total patient group of 147 patients, the predicted amount of alopecia was accurate in 90% of the cases. All inaccurate predictions overestimated the expected extent of alopecia. The presented straightforward method to visualize predicted alopecia 4 weeks after treatment has proven to predict the extent alopecia highly accurate in the vast majority of patients. Sharing these results with the patients pre-treatment may result in stress reduction before cranial irradiation.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Temporary alopecia is a common side-effect in brain tumour patients receiving cranial radiotherapy with a significant psychological burden for the affected patient. The purpose of this study was to generate a method in our treatment planning system (TPS) to visualize the expected radiation-induced alopecia 4 weeks after treatment, in order to inform the patients thereupon before the start of radiotherapy.
MATERIAL AND METHODS
METHODS
A pilot study was conducted in ten patients receiving hypo- (HF) or conventionally fractionated (CF) photon beam Volumetric Modulated Arc Therapy (VMAT) for an intracranial lesion. Dose calculations were correlated to visible alopecia four weeks after the end of treatment to create a structure predictive of alopecia in our TPS. These alopecia structures for both fractionation schedules were validated in two cohorts of 69 HF and 78 CF patients undergoing radiotherapy between 2016 and 2019.
RESULTS
RESULTS
In the pilot cohort, a total physical dose of 4 Gy for HF and 12.6 Gy for CF radiotherapy were found to be predictive of alopecia 4 weeks after treatment. Applying these doses to our validation cohort, we found an accurate prediction of alopecia in 59/69 (86%) HF and 73/78 (96%) CF patients. For the total patient group of 147 patients, the predicted amount of alopecia was accurate in 90% of the cases. All inaccurate predictions overestimated the expected extent of alopecia.
CONCLUSION
CONCLUSIONS
The presented straightforward method to visualize predicted alopecia 4 weeks after treatment has proven to predict the extent alopecia highly accurate in the vast majority of patients. Sharing these results with the patients pre-treatment may result in stress reduction before cranial irradiation.
Identifiants
pubmed: 35243020
doi: 10.1016/j.ctro.2022.02.003
pii: S2405-6308(22)00006-4
pmc: PMC8856945
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106-111Informations de copyright
© 2022 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Dtsch Dermatol Ges. 2018 Apr;16(4):435-461
pubmed: 29645394
N Engl J Med. 1999 Aug 12;341(7):491-7
pubmed: 10441606
Radiat Oncol. 2015 Nov 26;10:245
pubmed: 26611656
Radiat Res. 1998 Jan;149(1):11-8
pubmed: 9421149
Psychol Rep. 1990 Dec;67(3 Pt 1):775-8
pubmed: 2287669
J Invest Dermatol. 2004 Sep;123(3):455-7
pubmed: 15304082
J Appl Clin Med Phys. 2018 Mar;19(2):191-197
pubmed: 29411506
Arch Dermatol Res. 1995;287(3-4):279-84
pubmed: 7598533
Eur J Oncol Nurs. 2013 Jun;17(3):255-60
pubmed: 22901547
Lancet Oncol. 2013 Feb;14(2):e50-9
pubmed: 23369683
Indian J Dermatol Venereol Leprol. 2013 Sep-Oct;79(5):604-12
pubmed: 23974578
Front Oncol. 2020 Apr 08;10:467
pubmed: 32322558
J Cutan Med Surg. 2013 Jan-Feb;17(1):55-61
pubmed: 23364152
Radiother Oncol. 2020 Mar;144:127-134
pubmed: 31805517
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):879-87
pubmed: 15465206
Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30
pubmed: 10701741
Am J Clin Dermatol. 2018 Dec;19(6):853-865
pubmed: 30088232
Radiother Oncol. 2019 Jan;130:164-171
pubmed: 30033385
Clin Neurol Neurosurg. 2003 Jul;105(3):215-7
pubmed: 12860517
Cutis. 2008 Feb;81(2):147-53
pubmed: 18441767
Radiother Oncol. 2018 Jul;128(1):37-43
pubmed: 29548560
Med Phys. 2014 Aug;41(8):081720
pubmed: 25086530
JAMA Dermatol. 2020 Sep 1;156(9):963-972
pubmed: 32756880
Clin Dermatol. 2001 Mar-Apr;19(2):161-6
pubmed: 11397595